Serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease

Soham Rej,1 Mahwesh Saleem,2,3 Nathan Herrmann,1,3 Anthi Stefatos,4 Allison Rau,3 Krista L Lanctôt1–3 1Department of Psychiatry, 2Department of Pharmacology and Toxicology, University of Toronto, 3Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rej S, Saleem M, Herrmann N, Stefatos A, Rau A, Lanctôt KL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Cholesterol Visuospatial Cognition Heart Disease Psychopharmacology Adverse Drug Events Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/5349aca722cc4f3fa80bee510147b5a3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5349aca722cc4f3fa80bee510147b5a3
record_format	dspace
spelling	oai:doaj.org-article:5349aca722cc4f3fa80bee510147b5a32021-12-02T03:31:14ZSerum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease1178-2021https://doaj.org/article/5349aca722cc4f3fa80bee510147b5a32016-11-01T00:00:00Zhttps://www.dovepress.com/serum--low-density-lipoprotein-levels-statin-use-and-cognition-in-pati-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Soham Rej,1 Mahwesh Saleem,2,3 Nathan Herrmann,1,3 Anthi Stefatos,4 Allison Rau,3 Krista L Lanctôt1–3 1Department of Psychiatry, 2Department of Pharmacology and Toxicology, University of Toronto, 3Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, ON, 4Faculty of Medicine, Université de Montréal, Montréal, QC, Canada Aim: Statins have been associated with decreased cognition due to the effects of low concentrations of low-density lipoprotein (LDL) on brain function. This has remained controversial and is particularly relevant to patients with coronary artery disease (CAD), who have an increased risk of cognitive decline and are frequently prescribed statins. This study hypothesized that low concentration of LDL is associated with poor cognition in CAD patients using statins. It also explored the association between high-dose versus low-dose statins on cognition in this population. Patients and methods: Baseline cross-sectional data from a longitudinal study of 120 statin-using CAD patients were examined (mean statin duration 25±43 months). The main outcomes were measures of global cognition and cognitive domains, with poor cognition defined as cognitive performance ≤1 standard deviation below the population age and education adjusted means. A battery of cognitive tests was used to assess verbal memory, executive function, speed of processing, visuospatial memory, and global cognition. Adjusting for age, sex, education, and other covariates, multivariable logistic regression analyses assessed associations between low LDL levels (<1.5 mmol/L), statin use, and poor cognition. Results: LDL levels were not associated with global cognition or individual cognitive domains. High-dose statin use was associated with higher visuospatial memory (odds ratio, OR [95% confidence interval, CI] =0.12 [0.02–0.66], P=0.01) and executive functioning (OR =0.25 [0.06–0.99], P=0.05). This effect was independent of covariates such as LDL levels. Conclusion: Low LDL levels do not appear to be associated with poor cognition in CAD patients using statins. Whether high-dose statin use may have positive effects on cognition in CAD patients could be investigated in future studies. Keywords: cholesterol, visuospatial cognition, heart disease, psychopharmacology, adverse drug eventsRej SSaleem MHerrmann NStefatos ARau ALanctôt KLDove Medical PressarticleCholesterolVisuospatial CognitionHeart DiseasePsychopharmacologyAdverse Drug EventsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 12, Pp 2913-2920 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cholesterol Visuospatial Cognition Heart Disease Psychopharmacology Adverse Drug Events Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Cholesterol Visuospatial Cognition Heart Disease Psychopharmacology Adverse Drug Events Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Rej S Saleem M Herrmann N Stefatos A Rau A Lanctôt KL Serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease
description	Soham Rej,1 Mahwesh Saleem,2,3 Nathan Herrmann,1,3 Anthi Stefatos,4 Allison Rau,3 Krista L Lanctôt1–3 1Department of Psychiatry, 2Department of Pharmacology and Toxicology, University of Toronto, 3Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, ON, 4Faculty of Medicine, Université de Montréal, Montréal, QC, Canada Aim: Statins have been associated with decreased cognition due to the effects of low concentrations of low-density lipoprotein (LDL) on brain function. This has remained controversial and is particularly relevant to patients with coronary artery disease (CAD), who have an increased risk of cognitive decline and are frequently prescribed statins. This study hypothesized that low concentration of LDL is associated with poor cognition in CAD patients using statins. It also explored the association between high-dose versus low-dose statins on cognition in this population. Patients and methods: Baseline cross-sectional data from a longitudinal study of 120 statin-using CAD patients were examined (mean statin duration 25±43 months). The main outcomes were measures of global cognition and cognitive domains, with poor cognition defined as cognitive performance ≤1 standard deviation below the population age and education adjusted means. A battery of cognitive tests was used to assess verbal memory, executive function, speed of processing, visuospatial memory, and global cognition. Adjusting for age, sex, education, and other covariates, multivariable logistic regression analyses assessed associations between low LDL levels (<1.5 mmol/L), statin use, and poor cognition. Results: LDL levels were not associated with global cognition or individual cognitive domains. High-dose statin use was associated with higher visuospatial memory (odds ratio, OR [95% confidence interval, CI] =0.12 [0.02–0.66], P=0.01) and executive functioning (OR =0.25 [0.06–0.99], P=0.05). This effect was independent of covariates such as LDL levels. Conclusion: Low LDL levels do not appear to be associated with poor cognition in CAD patients using statins. Whether high-dose statin use may have positive effects on cognition in CAD patients could be investigated in future studies. Keywords: cholesterol, visuospatial cognition, heart disease, psychopharmacology, adverse drug events
format	article
author	Rej S Saleem M Herrmann N Stefatos A Rau A Lanctôt KL
author_facet	Rej S Saleem M Herrmann N Stefatos A Rau A Lanctôt KL
author_sort	Rej S
title	Serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease
title_short	Serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease
title_full	Serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease
title_fullStr	Serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease
title_full_unstemmed	Serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease
title_sort	serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/5349aca722cc4f3fa80bee510147b5a3
work_keys_str_mv	AT rejs serumlowdensitylipoproteinlevelsstatinuseandcognitioninpatientswithcoronaryarterydisease AT saleemm serumlowdensitylipoproteinlevelsstatinuseandcognitioninpatientswithcoronaryarterydisease AT herrmannn serumlowdensitylipoproteinlevelsstatinuseandcognitioninpatientswithcoronaryarterydisease AT stefatosa serumlowdensitylipoproteinlevelsstatinuseandcognitioninpatientswithcoronaryarterydisease AT raua serumlowdensitylipoproteinlevelsstatinuseandcognitioninpatientswithcoronaryarterydisease AT lanctotkl serumlowdensitylipoproteinlevelsstatinuseandcognitioninpatientswithcoronaryarterydisease
_version_	1718401728893681664

Serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease

Ejemplares similares